^
Association details:
| Biomarker: | EGFR C797S + EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)
Published date:
10/12/2022
Excerpt:
Furthermore, an EGFR C797S mutation was identified in plasma samples of an NSCLC patient with EGFR exon 20 insertion mutation who showed acquired resistance to mobocertinib using ddPCR.
